CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

NCT03263208 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

B-cell Acute Lymphocytic Leukemia

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: CD19 CAR-T

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]